Moderna gains 14% to $225 on reported NIH cancer vaccine push
Moderna closed up 14.2% at $225 on Friday as the New York Times reported an NIH-backed national effort to accelerate personalized cancer vaccines — on the same day the stock rejoined the Nasdaq-100.
